Urology Diagnostics
Urology Diagnostics provides early, noninvasive cancer detection and monitoring using urine-based genomic analysis and machine learning to produce clinically actionable risk assessments. The company applies nucleic acid sequencing from urine (liquid biopsy) combined with genomic feature analysis and ML models to detect cancer-associated signals and contextualize results with clinical evidence. It operates in the precision medicine diagnostics category and targets clinicians, clinical laboratories, and health systems for screening and patient surveillance. Key technologies include urine liquid biopsy, nucleic acid sequencing, genomics, and machine learning. The approach supports less invasive, repeatable testing for early detection and longitudinal monitoring.
Urology Diagnostics
Urology Diagnostics provides early, noninvasive cancer detection and monitoring using urine-based genomic analysis and machine learning to produce clinically actionable risk assessments. The company applies nucleic acid sequencing from urine (liquid biopsy) combined with genomic feature analysis and ML models to detect cancer-associated signals and contextualize results with clinical evidence. It operates in the precision medicine diagnostics category and targets clinicians, clinical laboratories, and health systems for screening and patient surveillance. Key technologies include urine liquid biopsy, nucleic acid sequencing, genomics, and machine learning. The approach supports less invasive, repeatable testing for early detection and longitudinal monitoring.